OLFML3 and neoplasm: The combination of anti-OLFML3 and anti-PD-1 antibodies increases tumor infiltration by inflammatory myeloid cells, B cells, T lymphocytes, and NKT cells, and inhibits tumor growth more effectively than either agent used alone.